Replies to post #9886 on Aurinia Pharmaceuticals Inc (AUPH)

[biotech_researcher]

Ariad - patients, after being on their approved CML drug, Ponatinib, developed severe side effects (death, limb removal). Stock dropped from $24 to $3. Drug was pulled but in 9-12 months, drug was re-introduced, but using a tapered dose from the beginning. This worked. Stock didn’t do much until Takeda saved the day and bought Ariad for $24 and change.

[Jesspro]

Wow! We haven’t been through savoring the P3 data Yet and here comes another round of sowing doubt. LTD, there was a boxed warning for that Ariad drug and the shorts triumphantly pushed that narrative. In this case, I don’t care if they have 10 AF to help the shorts this time, this one is taking off without any hitch. With those p-values attached in all categories, only an act of GOD can stop this trek to the north. This is 99% fire proof. The only thing that will derail this is a faux p3 data. We were hoping for a BO of 30/40 with that Ariad drug but 24 is more than enough for a 5.50 cost basis...Jmho.